CDMOs have several potential growth drivers, including biologics demand, GLP-1 manufacturing, outsourcing and programs advancing toward commercial production. But the available company disclosures do not establish that the sector will outperform a defined benchmark—or that every provider will benefit. A useful outlook therefore separates demand signals from the harder work of qualifying capacity, winning commercial programs and converting them into revenue and returns.
Can CDMO players maintain outperformance?
It is possible for some CDMOs to grow strongly, but “outperformance” has no precise meaning without a benchmark, peer group and time horizon. The company materials discussed here are management outlooks, operating updates and presentations, not an independent sector forecast or a like-for-like ranking of providers.
As an Amazon Associate I earn from qualifying purchases.
A CDMO, or contract development and manufacturing organization, provides pharmaceutical and biotechnology companies with some combination of drug development and manufacturing. Providers differ by modality and service: one may focus on biologics or drug substance, another on sterile injectables, fill-finish or delivery systems. A demand trend benefits a company only where its capabilities, customer programs and available capacity match that demand.
Which growth triggers could support CDMO demand?
Biologics and other complex modalities
Biologics and specialized manufacturing can require dedicated processes, technical expertise and qualified capacity. Lonza’s 8 May 2026 Q1 business update reported momentum across Integrated Biologics, Advanced Synthesis and Specialized Modalities, illustrating why it is more useful to examine demand by platform than to treat “biologics” as one uniform market. Lonza also said it continued to see outsourcing demand from large pharma and biotech companies; that is the company’s characterization, not an independent measurement of sector demand.
#1 Best Overall
GLP-1 and obesity-related manufacturing
GLP-1-related opportunities can span drug substance, sterile fill-finish and delivery systems. OneSource Specialty Pharma said its drug-delivery capacity investment and accelerated phase-two expansion were aimed in part at GLP-1 commercialization. Stevanato Group identified GLP-1 therapies among its focus areas. Those disclosures show where the companies are positioning their operations; they do not establish how much revenue a specific program will generate.
There is also a counterweight: major pharmaceutical companies can build or expand their own supply chains. Novo Nordisk’s Q2 2026 presentation describes internal high-volume biologics and API manufacturing capabilities, as well as filling, tableting and finishing operations. Its H1 2026 report discusses planned investment and flexibility across API, aseptic and finished production, and packaging. Its materials also discuss pricing and competition alongside demand and investment, underscoring that higher end-market demand does not automatically mean higher prices or better economics for outside suppliers.
Outsourcing, integrated work and repeat customers
Companies may award a provider connected development and manufacturing work, or extend a relationship as a program advances. Lonza reported multiple integrated drug-substance-to-drug-product contracts secured in Q1 2026. OneSource reported that more than 70% of its new business wins came from existing customers in its Q3 FY26 presentation. Repeat business and integrated contracts may improve visibility, but the value depends on contract terms, program timing, customer concentration and whether projects reach commercial scale.
Free tools Windows power users keep installed
One-click scans. No signup required.
Biosimilars and supply-chain diversification
OneSource described biosimilar customer wins and biologics supply-chain diversification as opportunities. These are company-described catalysts, not evidence that each program is already in commercial production. Before assigning a contribution to a particular win, investors need to know its development or launch status, expected scale and commercial economics.
What company disclosures say about growth and capacity
The figures below are company-specific outlooks, targets or milestones—not comparable sector forecasts. Different metrics and periods should not be ranked as if they measured the same thing.
| Company or issuer | Disclosed outlook or milestone | How to interpret it |
|---|---|---|
| Lonza | In its 8 May 2026 business update, Lonza confirmed 2026 sales growth guidance of 11–12% at constant exchange rates and a core EBITDA margin above 32%. | These are company outlook figures. Lonza expected growth and margin to be notably stronger in H1 than H2, citing the prior-year base, campaign timing, product releases and planned shutdowns; it also cited foreign-exchange headwinds to sales. |
| OneSource Specialty Pharma | Its Q3 FY26 presentation set an FY25–FY28 revenue CAGR target above 30%, steady-state EBITDA of about 40%, targeted ROCE above 50% and net debt-to-EBITDA below 1.5x. It showed FY28 revenue outlook of $400 million organically and $500 million-plus in a proposed-acquisition scenario. | These are company targets and outlooks, not realized results. The higher FY28 scenario depends on the proposed acquisition. The presentation also described a $75 million drug-delivery capacity investment and said phase two of an expansion had been brought forward. |
| Stevanato Group | Its Q2 2026 results presentation reported qualification of its first EZ-fill vial line and anticipated customer validations. It described planned prefilled-syringe and cartridge capacity in EMEA, and expected contract drug-delivery-system production to begin at the end of 2026. | Qualification, anticipated validations and expected production are separate milestones. The presentation describes management plans; it does not establish that the expected production start or future capacity utilization has since been achieved. |
| Sterile-injectables CDMO described in an SEC-filed presentation | A 2026 presentation set management goals of revenue CAGR above 12% and adjusted EBITDA margin above 25%, alongside a three-part plan: expand existing-customer business, advance late-stage programs toward commercialization and win new business. | The exhibit is associated with Laboratory Corporation of America Holdings, while the presentation describes a sterile-injectables CDMO. Because the issuer’s identity and peer comparability are not clear from the available information, these goals should not be used to rank a named CDMO. They are forward-looking management goals, and the presentation warns actual results may differ materially. |
Why capacity announcements are not the same as growth
A new line or facility is an opportunity to serve customers, not revenue on its own. A program generally has to move through several stages before added capacity contributes meaningfully to reported results:
Rank #4
- Commissioning: the facility or equipment is installed and operating as intended.
- Qualification: the manufacturer demonstrates that the process and facility meet applicable requirements.
- Customer validation: the customer confirms the process works for its product and requirements.
- Commercial production: the product enters commercial manufacturing, subject to program timing and demand.
- Utilization and returns: production fills enough available capacity to support revenue and an acceptable return on the capital invested.
Stevanato’s qualified vial line and anticipated customer validations illustrate why those steps should not be collapsed into a single “capacity added” claim. Lonza’s Vacaville large-scale mammalian capacity is another example: its May 2026 update said interest remained high, but customer interest is not the same as production, utilization or recognized revenue.
What could prevent growth from translating into outperformance?
- Timing and execution: qualification, validation, product release and commercial ramp schedules can shift. Lonza’s explanation of its uneven expected half-year profile shows how campaigns and planned shutdowns can affect the timing of results.
- Customer concentration: a small number of large customers or late-stage programs can make results dependent on individual decisions, launches and production schedules. Repeat wins are valuable context, but they do not by themselves show how diversified future revenue will be.
- In-house production and competition: customers may add internal capacity, as Novo Nordisk’s manufacturing disclosures illustrate, or use other providers. Industry demand does not necessarily translate into incremental outsourced work.
- Pricing and margins: high demand does not guarantee pricing power. Novo Nordisk’s discussion of GLP-1 pricing and competition is a reminder that demand, realized prices and supplier economics can move differently.
- Capital intensity and utilization: expansions require investment and can weigh on returns if customer programs are delayed or capacity remains underused. Growth should be assessed alongside spending, debt, utilization and returns on new assets.
- Foreign exchange and operating schedules: reported growth and profitability can differ from underlying activity because of currency movements, campaign timing, releases and outages. Check each company’s metric definition and period before comparing results.
How to assess which CDMOs are best positioned
Rather than treating the sector as one trade, compare companies across the parts of the business that actually determine conversion from demand to earnings:
- Technology and service mix: identify exposure to biologics, small molecules, sterile injectables, fill-finish, drug substance, drug product and delivery systems.
- Program maturity: distinguish development-stage wins from customer-validated programs and active commercial production.
- Capacity execution: track commissioning, qualification, customer validation, utilization, site concentration and planned outages.
- Customer and program mix: examine dependence on a small number of customers or products, while considering whether repeat business is translating into durable, diversified revenue.
- Economics: compare growth with margins, pricing, currency exposure, capital needs, leverage and returns on new capacity.
- Competitive position: consider what customers retain in-house, what they outsource and whether a given award represents new external demand or a transfer of existing work.
On the disclosures available, Lonza offers a near-term company outlook, OneSource presents ambitious multi-year targets and a conditional acquisition scenario, and Stevanato reports capacity and customer-validation milestones. Those are different kinds of evidence, not a defensible peer ranking. A conclusion about which CDMO will outperform requires comparable reported results for a defined set of providers and a stated benchmark and period.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
